Literature DB >> 8261875

Methadone dose and treatment outcome.

E C Strain1, M L Stitzer, I A Liebson, G E Bigelow.   

Abstract

Consensus on the optimal dosing of methadone in the treatment of opioid dependence has not yet been achieved, with some programs committed to low dose regimens. This paper presents outcome results for 95 opioid abusers who remained in treatment through a stable dosing period in a double-blind fixed dose clinical trial comparing the relative efficacies of 50 (n = 44) and 20 mg (n = 34) of methadone to methadone-free treatment (n = 17). All patients showed improvements over time on measures of psychosocial functioning and psychological symptoms, emphasizing the important role of non-pharmacologic factors in methadone treatment. Furthermore, orderly dose effect relationships were seen, with patients receiving 50 mg of methadone having significantly lower rates of opioid positive urines (36% vs. 60-73%), and self-reporting a lower frequency of heroin use (3 days vs. 11-12 days per month). These results illustrate the dose-related efficacy of methadone in decreasing illicit opioid use and improving drug-related behavior.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8261875     DOI: 10.1016/0376-8716(93)90052-r

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  18 in total

1.  Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting.

Authors:  C Patrick Carroll; Michael Kidorf; Eric C Strain; Robert K Brooner
Journal:  J Subst Abuse Treat       Date:  2007-04-02

2.  Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.

Authors:  Sandra D Comer; Maria A Sullivan; Suzanne K Vosburg; Jeanne Manubay; Leslie Amass; Ziva D Cooper; Phillip Saccone; Herbert D Kleber
Journal:  Addiction       Date:  2010-04       Impact factor: 6.526

3.  Pharmacotherapy in the treatment of addiction: methadone.

Authors:  Mary Jeanne Kreek; Lisa Borg; Elizabeth Ducat; Brenda Ray
Journal:  J Addict Dis       Date:  2010-04

4.  Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency.

Authors:  David H Epstein; John Schmittner; Annie Umbricht; Jennifer R Schroeder; Eric T Moolchan; Kenzie L Preston
Journal:  Drug Alcohol Depend       Date:  2008-12-19       Impact factor: 4.492

Review 5.  Methadone maintenance treatment: an update.

Authors:  G Bertschy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  A randomized investigation of methadone doses at or over 100 mg/day, combined with contingency management.

Authors:  Ashley P Kennedy; Karran A Phillips; David H Epstein; David A Reamer; John Schmittner; Kenzie L Preston
Journal:  Drug Alcohol Depend       Date:  2012-11-26       Impact factor: 4.492

7.  The nature of methadone diversion in England: a Merseyside case study.

Authors:  Paul Duffy; Helen Baldwin
Journal:  Harm Reduct J       Date:  2012-01-13

8.  Determining effective methadone doses for individual opioid-dependent patients.

Authors:  Jodie A Trafton; Jared Minkel; Keith Humphreys
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

Review 9.  Therapeutic options and challenges for substances of abuse.

Authors:  Tracie J Gardner; Thomas R Kosten
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

10.  Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.

Authors:  Tessa Nalven; Nichea S Spillane; Melissa R Schick; Lisa L Weyandt
Journal:  Exp Clin Psychopharmacol       Date:  2021-07-05       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.